Natalizumab in the treatment of Crohn's disease

Biologics: Targets and Therapy

Volumn 2, Issue 2, 2008, Pages 275-284

  Guagnozzi, Danila ^a   Caprilli, Renzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biological therapy; Crohn's disease; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

EID: 77957673514     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Adelman B, Sandrock A, Panzara MA. 2005. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med, 353:432-3.
2. Alon R, Kassner PD, Carr MW, et al. 1995. The integrins VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol, 128: 1243-53.
3. Berger JR, Koralnik IJ. 2005. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med, 353:414-6.
4. Berlin C, Bargatze RF, Campbell JJ, et al. 1995. Alpha4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell, 80:413-22.
5. Binion DG, West GA, Volk EE, et al. 1998. Acquired increase in luokocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet, 352:1742-6.
6. Brennan DC, Agha I, Bohl DL, et al. 2005. Incidence of BK with tracolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant, 5:582-94.
7. Butcher EC, Picker LJ. 1996. Lymphocyte homing and homeostasis. Science, 272:60-9.
8. Casini B, Borghese L, Del Nonno F, et al. 2005. Presence and incidence of DNA sequences of human polyomavirus BKV and JCV in colorectal tumor tissue. Anticancer Res, 25:1079-85.
9. Elan Pharma (Europe) Ltd. 1997. A phase I double-blind, placebo-controlled, ascending single intravenous dose, safety, tolerability, pharmacokinetic, immunogenicity and potency study in healthy male volunteers. Athena report nr. AN100226-101.
10. Fiocchi C. 1998. Inflammatory bowel disease:etiology and pathogenesis. Gastroenterology, 115:182-205.
11. Gosh S, Goldin E, Gordon FH, et al. 2003. Natalizumab for active Crohn's disease. N Eng J Med, 348:24-32.
12. Gordon FH, Clement WYL, Hamilton MI, et al. 2001. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology, 121:268-74.
13. Gordon FH, Hamilton MI, Donoghue S, et al. 2002. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha4 integrin. Aliment Pharmacol Ther, 16:699-705.
14. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. 1996. Rapid resolution of chroic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology, 111:1373-80.
15. Hynes RO. 2002. Integrins:bidirectional, allosteric signalling machines. Cell, 110:673-87.
16. Kleinschmidt-DeMasters BK, Tyler KL. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med, 353:369-74.
17. Kubes P, Niu XF, Smith CW, et al. 1995. A novel beta 1-dependent adhesion pathway on neutrophils:a mechanism invoked by dihydrocytochalasin B or endothelial transmigration. FASEB J, 9:1103-11.
18. Langer-Gould A, Atlas SW, Green AJ, et al. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med, 353:375-81.
19. MacDonald JK, McDonald JWD. 2007. Natalizumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews, 2007 Issue 1.
20. Miller DH, Khan OA, Sherenta WA, et al. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 348:15-23.
21. Modigliani R, Mary JY, Simon JF, et al. 1990. Clinical biological and endoscopical picture of attacks of Crohn's disease:evolution on prednisolone. Groupe d'etude therapeutique des affections inflammatoires digestives. Gastroenterology, 98:811-8.
22. Nakamura K, Honda K, Mizutani T, et al. 2006. Novel strategies for the treatment of inflammatory bowel disease:selective inhibition of cytokines and adhesion molecules. World J Gastroenterol, 12:4628-35.
23. Niv Y, Goel A, Boland CR. 2005. JC virus and colorectal cancer: a possible trigger in the chromosomal instability pathways. Curr Opin Gastroenterol, 21:85-9.
24. Oldenburg B, Hommes D. 2007. Biological therapies in inflamatory bowel disease:top-down or bottom-up? Curr Opin Gastroenterol, 23:395-99.
25. Picarella D, Hurbut P, Rottman J, et al. 1997. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhighCD4+ T-cells. J immunol, 158:2099-106.
26. Podolsky DK, Lobb R, King N, et al. 1993. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibosy. J Clin Invest, 92:372-80.
27. Podolsky DK. 2005. Selective adhesion-molecule therapy and inflamatory bowel disease-a tale of Janus? N Engl J Med, 353:1965-8.
28. Sandborn WJ, Colombel JF, Enns R, et al. 2005. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med, 353:1912-25.
29. Soriano A, Salas A, Salas A, et al. 2000. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest, 80:1541-51.
30. Springer TA. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration:the multistep system. Cell, 76:301-14.
31. Stephens LE, Sutherland AE, Klimanskaya IV, et al. 1995. Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. Genes Dev, 9:1883-95.
32. Targan SR, Feagan BG, Fedorak RN et al. 2007. Ntalizumab for the treatment of active Crohn's disease:results of the ENCORE trial. Gastroenterology, 132:1672-83.
33. Van Assche G, Van Ranst M, Sciot R, et al. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med, 353:362-8.
34. Von Andrian UH, Mackay CR. 2000. T-cell function and migration:two sides of the same coin. N Engl J Med, 343:1020-34.
35. Yednock TA, Cannon C, Frits LC, et al. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature, 356:63-6.
36. Yousry TA, Habil M, Majot EO, et al. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med, 354:924-33.